Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy
Abstract The aim of the present study was to investigate the usefulness of multidrug resistance protein 1 (MDR1) and neuropeptide Y (NPY) levels in predicting the efficacy of levetiracetam (LEV) plus oxcarbazepine (OXC) treatment administered to children with epilepsy and to determine their prognosi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2023-05-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100339&lng=en&tlng=en |
| _version_ | 1827951533854031872 |
|---|---|
| author | Jiahong Wang |
| author_facet | Jiahong Wang |
| author_sort | Jiahong Wang |
| collection | DOAJ |
| description | Abstract The aim of the present study was to investigate the usefulness of multidrug resistance protein 1 (MDR1) and neuropeptide Y (NPY) levels in predicting the efficacy of levetiracetam (LEV) plus oxcarbazepine (OXC) treatment administered to children with epilepsy and to determine their prognosis. Overall, 193 children with epilepsy admitted to the hospital were enrolled and randomly divided into two groups according to different treatment methods: group A (n = 106, treated with LEV plus OXC combination) and group B (n = 87, treated with OXC only). After treatment, compared with group B, group A exhibited a remarkably higher total effective rate and a significantly lower total adverse reaction rate. Areas under the curve for MDR1 and NPY for predicting ineffective treatment were 0.867 and 0.834, whereas those for predicting epilepsy recurrence were 0.916 and 0.829, respectively. Electroencephalography abnormalities, intracranial hemorrhage, neonatal convulsion, premature delivery, and MDR1 and NPY levels were independent risk factors for poor prognosis in children with epilepsy. Serum MDR1 and NPY levels exhibited a high predictive value for early epilepsy diagnosis, treatment efficacy assessment, and prognostication in children with epilepsy treated with LEV plus OXC combination. |
| first_indexed | 2024-04-09T13:43:15Z |
| format | Article |
| id | doaj.art-f52f1353e3a64c2283178ff2b834e7ee |
| institution | Directory Open Access Journal |
| issn | 2175-9790 |
| language | English |
| last_indexed | 2024-04-09T13:43:15Z |
| publishDate | 2023-05-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-f52f1353e3a64c2283178ff2b834e7ee2023-05-09T07:33:12ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902023-05-015910.1590/s2175-97902023e21414Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with EpilepsyJiahong Wanghttps://orcid.org/0000-0002-6078-3575Abstract The aim of the present study was to investigate the usefulness of multidrug resistance protein 1 (MDR1) and neuropeptide Y (NPY) levels in predicting the efficacy of levetiracetam (LEV) plus oxcarbazepine (OXC) treatment administered to children with epilepsy and to determine their prognosis. Overall, 193 children with epilepsy admitted to the hospital were enrolled and randomly divided into two groups according to different treatment methods: group A (n = 106, treated with LEV plus OXC combination) and group B (n = 87, treated with OXC only). After treatment, compared with group B, group A exhibited a remarkably higher total effective rate and a significantly lower total adverse reaction rate. Areas under the curve for MDR1 and NPY for predicting ineffective treatment were 0.867 and 0.834, whereas those for predicting epilepsy recurrence were 0.916 and 0.829, respectively. Electroencephalography abnormalities, intracranial hemorrhage, neonatal convulsion, premature delivery, and MDR1 and NPY levels were independent risk factors for poor prognosis in children with epilepsy. Serum MDR1 and NPY levels exhibited a high predictive value for early epilepsy diagnosis, treatment efficacy assessment, and prognostication in children with epilepsy treated with LEV plus OXC combination.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100339&lng=en&tlng=enLevetiracetamOxcarbazepineChildren with epilepsyMultidrug resistance protein 1Neuropeptide YEfficacy |
| spellingShingle | Jiahong Wang Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy Brazilian Journal of Pharmaceutical Sciences Levetiracetam Oxcarbazepine Children with epilepsy Multidrug resistance protein 1 Neuropeptide Y Efficacy |
| title | Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy |
| title_full | Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy |
| title_fullStr | Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy |
| title_full_unstemmed | Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy |
| title_short | Levetiracetam plus Oxcarbazepine Combination Treatment Downregulates Serum Multidrug Resistance Protein 1 Levels and Upregulates Neuropeptide Y Levels in Children with Epilepsy |
| title_sort | levetiracetam plus oxcarbazepine combination treatment downregulates serum multidrug resistance protein 1 levels and upregulates neuropeptide y levels in children with epilepsy |
| topic | Levetiracetam Oxcarbazepine Children with epilepsy Multidrug resistance protein 1 Neuropeptide Y Efficacy |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100339&lng=en&tlng=en |
| work_keys_str_mv | AT jiahongwang levetiracetamplusoxcarbazepinecombinationtreatmentdownregulatesserummultidrugresistanceprotein1levelsandupregulatesneuropeptideylevelsinchildrenwithepilepsy |